01 / THE TARGET
Visceral abdominal fat
The relevant study outcomes concern internal abdominal fat in a defined population—not general body-weight loss.
TESAMORELIN. FACTS THAT GO DEEPER.
Tesamorelin.
Beyond the Scale.
Not all belly fat is the same. Get straight to visceral fat, how tesamorelin engages the GH pathway, and what clinical research has actually measured. The details that matter, without the noise.Visceral fat. The GH pathway. What the research shows. Explore tesamorelin, then connect in one tap.
BangkokSame-day delivery
Thailand-wide1–2 day express
GH pathwayVisceral fatClinical evidence
BEYOND THE WAISTLINEThe science of visceral fat
Product format
Tesamorelin
฿1,950
10 mg · Vial · Catalogue price
VISUAL CUE
VISCERAL FAT / VISUAL GUIDE
VISCERAL FAT / VISUAL GUIDE
01 / THE ANATOMY
Not All Belly Fat Is the Same.
Most people see the waistline. The science goes deeper. Visceral fat surrounds abdominal organs; subcutaneous fat sits under the skin. Learn why the difference matters in clinical studies.
INTERACTIVE / 2 TISSUE TYPES
See What Sits Beneath.
Use the selector to highlight each layer on a simplified anatomical cross-section. The diagram shows location, not an individual medical scan.
Visceral — the deeper compartment
Located inside the abdominal cavity around internal organs. It is the specific fat compartment central to tesamorelin's studied U.S. clinical indication.
Subcutaneous / outerVisceral / inner
02 / THE MOLECULE
Tesamorelin. Know the Mechanism.
Tesamorelin isn't HGH. It acts upstream as a growth hormone-releasing factor analog, stimulating the pathway behind the body's own GH release.
01 / COMPOUND
Tesamorelin
A synthetic growth hormone-releasing factor analog.
02 / TARGET
Pituitary
Stimulation of the pituitary promotes endogenous GH release.
03 / SIGNAL
GH / IGF-1
Downstream effects involve growth hormone and IGF-1 signalling.
04 / OUTCOME
Research
Clinical outcomes must be understood in their studied populations.
Source: U.S. DailyMed / EGRIFTA WR prescribing information (updated July 2026).
03 / THE EVIDENCE
The Clinical Evidence. Not the Hype.
Go beyond sweeping claims. See who was studied, what researchers measured, and how to understand the findings in their proper clinical context.
U.S. LABEL / CLINICAL CONTEXT
A Specific Indication. Know the Facts.
In the U.S., EGRIFTA WR (tesamorelin) is indicated for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. The label specifically states that it is not indicated for weight-loss management.
Read the official U.S. label ↗02 / THE LIMITS
Long-term safety
The U.S. label notes that long-term cardiovascular safety has not been established.
03 / THE FORMULATION
Products differ
Prescription formulations have their own label and preparation directions. EGRIFTA WR and SV are not interchangeable.
04 / RECOGNISE THE PRODUCT FORM
Vial or Pen? Know the Difference.
When comparing tesamorelin product images, check the exact presentation rather than assuming all packaging contains the same formulation. These are illustrations of different formats from an external catalogue, not photos of approved EGRIFTA products.
The pictured 10 mg catalogue vial is not a photograph of the U.S.-approved EGRIFTA WR 11.6 mg formulation. Concentrations, instructions and regulatory status should not be assumed equivalent.
Vial exampleRogue Mass image
Pen exampleRogue Mass image
05 / THE ESSENTIAL QUESTIONS
Tesamorelin FAQs. Straight Answers.
What is tesamorelin?
Tesamorelin is a synthetic analog of growth hormone-releasing factor. It acts on the pituitary to stimulate endogenous growth hormone release, with downstream effects on IGF-1.
Is tesamorelin the same as HGH?
No. HGH (somatropin) is growth hormone itself. Tesamorelin acts upstream in the hormonal signalling pathway. They are not interchangeable molecules.
Why does visceral fat feature in the studies?
Visceral adipose tissue is fat deeper in the abdominal cavity. Tesamorelin's U.S.-approved indication concerns excess abdominal fat in adults with HIV-associated lipodystrophy, and relevant trials assessed changes in that setting.
Is tesamorelin approved for routine weight loss?
The U.S. EGRIFTA WR label says it is not indicated for weight-loss management. U.S. regulatory wording should not be confused with approval status in Thailand.
Are all tesamorelin vials equivalent?
No. The FDA label specifically distinguishes EGRIFTA WR from EGRIFTA SV. Other catalogue products should not be presumed equivalent to either formulation.
Tesamorelin Format Questions? Ask Directly.
Need details on different tesamorelin formats? Rogue Mass handles external catalogue enquiries. Ask directly through WhatsApp, Telegram or LINE; this guide does not provide clinical consultations.